Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)

Robert F. Asbury*, Stuart Lipsitz, David Graham, Carla I. Falkson, Luis Baez, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

Original languageEnglish (US)
Pages (from-to)45-46
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number1
DOIs
StatePublished - Feb 2000

Keywords

  • Esophageal cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)'. Together they form a unique fingerprint.

Cite this